Mr. Hugh Rogers reports

BIONXT ACCELERATES R&D WITH MOVE TO GEN-PLUS LABORATORY IN MUNICH, GERMANY, EXPANDING DRUG DELIVERY RESEARCH CAPABILITIES

Bionxt Solutions Inc. has provided an update on a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D (research and development) activities to the Gen-Plus contract research and development organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores Bionxt's commitment to scientific innovation and advancing solutions for unmet medical needs.

The new laboratory facility provides Bionxt with access to cutting-edge technologies, an expanded 1,000-square-metre research environment and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's continuing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics and next-generation biomedical technologies.

Bionxt relocates to Gen-Plus -- strategic importance for advanced R&D

By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, Bionxt aims to harness the facility's 1,000 square metres of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant (good manufacturing practice) processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower Bionxt to:

• Enhance R&D capabilities: With access to cutting-edge equipment and analytical tools, Bionxt is better positioned to develop innovative solutions and optimize its research outcomes.
• Foster collaborations: The Munich location enables proximity to leading research institutions, biotech firms and academic experts, paving the way for impactful partnerships.
• Accelerate innovation: The advanced resources at Gen-Plus laboratory allow Bionxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.

"Bionxt's transition to Gen-Plus marks a pivotal moment for Bionxt," said Hugh Rogers, chief executive officer of Bionxt Solutions. "This transition is both strategic and timely and unlocking new possibilities for added strength on IP [intellectual property] with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing impact on current and future projects."

Bionxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy and streamline the development of next-generation therapeutics.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.